HRP20151111T1 - Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora - Google Patents
Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora Download PDFInfo
- Publication number
- HRP20151111T1 HRP20151111T1 HRP20151111TT HRP20151111T HRP20151111T1 HR P20151111 T1 HRP20151111 T1 HR P20151111T1 HR P20151111T T HRP20151111T T HR P20151111TT HR P20151111 T HRP20151111 T HR P20151111T HR P20151111 T1 HRP20151111 T1 HR P20151111T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrimidinyl
- methyl
- pyridinyl
- phenyl
- group
- Prior art date
Links
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000008584 quinuclidines Chemical class 0.000 title 1
- -1 quinaxolinyl Chemical group 0.000 claims 335
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000004076 pyridyl group Chemical group 0.000 claims 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 8
- 125000000335 thiazolyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000006396 chloropyrazinyl group Chemical group 0.000 claims 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- ZHQSBSGAHYOIQE-UHFFFAOYSA-N 2-bromoquinazoline Chemical compound C1=CC=CC2=NC(Br)=NC=C21 ZHQSBSGAHYOIQE-UHFFFAOYSA-N 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000006402 chloropyridazinyl group Chemical group 0.000 claims 2
- 125000006390 chloropyrimidinyl group Chemical group 0.000 claims 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000006399 methylpyrazinyl group Chemical group 0.000 claims 2
- 125000006405 methylpyridazinyl group Chemical group 0.000 claims 2
- 125000006393 methylpyrimidinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Claims (14)
1. Spoj formule I, ili njegov stereoizomer,
[image]
gdje
R1 se izabire iz grupe koja obuhvaća izoksazolil, pirazolil, oksazolil, tiazolil, imidazolil, oksadiazolil, tiadiazolil, triazolil, piridinil, pirazinil, piridazinil, pirimidinil, triazinil, kinolinil, izokinolinil, kinoksalinil, kinaksolinil, naftiridinil, indazolil, indolil, 2-indolonil, benzizoksazolil, benzoizotiazolil, benzoksazolil, benzotiazolil, benzimidazolil, furopiridinil., tienopiridinil, tienopirimidinil, izotiazolopiridinil, tiazolopiridinil, tiazolopiridinonil, tiazolopirazinil, tiazolopirimidinil, triazolopiridinil, triazolopirazinil, pirolotriazinil, 5,6-dihidrobenzo[h]kinazolinil, 5H-kromeno[4,3-d]pirimidinil, 6,7-dihidro-5H-ciklopenta[d]pirimidinil, 5,6,7,8-tetrahidrokinazolinil, 7,8-dihidrokinazolin-5(6H)-onil, i tetrahidrobenzotiazolil, i supstituiran je s 0-3 supstituenta nezavisno izabrana iz grupe koja obuhvaća C1-4alkil, C3-7cikloalkil, C1-4haloalkil, C1-4alkoksi, C1-4haloalkoksi, C3-7cikloalkoksi, C1-4alkiltio, fenoksi, benziloksi, halo, hidroksi, cijano, C1-4alkilsulfonil, NR2R3, pirolidinonil, metilendioksi, furil, tienil, triazolil, pirimidinil, naftil, C1-4alkilamido, CONR2R3, piridil, fenil, i benzil, i gdje su piridil, fenil i benzil supstituirani s 0-2 supstituenta nezavisno izabrana iz grupe koja obuhvaća halo, C1-4alkil, C1-4alkoksi, C1-4haloalkil, C1-4haloalkoksi, i NR2R3;
R2 je vodik, C1-4alkil, C1-4hidroksialkil, ili C1-4aminoalkil;
R3 je vodik, C1-4alkil, C1-4hidroksialkil, ili C1-4aminoalkil;
ili R2 i R3 uzet zajedno s atomom dušika na koji je spojen jest azetidinil, pirolidinil, piperidinil, piperazinil, N-(C1-4alkil)piperazinil, morfolinil, ili homopiperidinil;
ili njegova farmaceutski prikladna sol.
2. Spoj prema zahtjevu 1 gdje R1 se izabire iz grupe koja obuhvaća dimetilizoksazolil, (metil)(fenil)izoksazolil, metilpirazolil, dimetilpirazolil, tienilpirazolil, metoksifenilpirazolil, tiazolil, bromotiazolil, cijanotiazolil, metiltiazolil, dimetiltiazolil, (metil)(fenil)tiazolil, izopropiltiazolil, butiltiazolil, benziltiazolil, metoksifenilmetiltiazolil, feniltiazolil, klorofeniltiazolil, metoksifeniltiazolil, (metoksifenil)(metil)tiazolil, piridiniltiazolil, (fenil)(metil)imidazolil, metiloksadiazolil, etiloksadiazolil, metiltiadiazolil, fluorofeniltiadiazolil, furiltiadiazolil, (dimetilkarboksamido)(metil)tiazolil, (pirolidinilCO)tiazolil, feniltriazolil, piridinil, bromopiridinil, kloropiridinil, (kloro)(fluoro)piridinil, (kloro)(metil)piridinil, dikloropiridinil, fluoropiridinil, cijanopiridinil, (cijano)(metil)piridinil, (cijano)(dimetil)piridinil, metoksipiridinil, (metilpirolidinil)piridinil, fenilpiridinil, metoksipiridinilpiridinil, piridazinil, bromopiridazinil, kloropiridazinil, metilpiridazinil, metoksipiridazinil, metiltiopiridazinil, pirolidinilpiridazinil, pirolidinonilpiridazinil, fenilpiridazinil, piridinilpiridazinil, metoksipiridinilpiridazinil, pirimidinil, (bromo)(izopropil)pirimidinil, (bromo)(dimetil)pirimidinil, (bromo)(ciklopropil)pirimidinil, (bromo)(metoksi)pirimidinil, (bromo)(fenil)pirimidinil, (bromo)(piridinil)pirimidinil, kloropirimidinil, (kloro)(dimetil)pirimidinil, (metil)(metoksi)pirimidinil, metilpirimidinil, etilpirimidinil, (metil)(fenil)pirimidinil, dimetilpirimidinil, butilpirimidinil, izopropilpirimidinil, ciklopropilpirimidinil, metoksipirimidinil, dimetoksipirimidinil, izopropoksipirimidinil, ciklopentoksipirimidinil, difluorometoksipirimidinil, trifluoroetoksipirimidinil, fenoksipirimidinil, metiltiopirimidinil, fenilpirimidinil, klorofenilpirimidinil, metilfenilpirimidinil, metoksifenilpirimidinil, (fenil)(triazolil)pirimidinil, piridinilpirimidinil, metoksipiridinilpirimidinil, metoksipirimidinilpirimidinil, naftilpirimidinil, pirazinil, bromopirazinil, (bromo)(metoksi)pirazinil, kloropirazinil, metilpirazinil, dimetilpirazinil, butilpirazinil, cijanopirazinil, metoksipirazinil, izopropoksipirazinil, trifluorometilpirazinil, i fenilpirazinil, i dimetiltriazinil;
ili njegova farmaceutski prikladna sol.
3. Spoj prema zahtjevu 1 gdje R1 se izabire iz grupe koja obuhvaća dimetilpiridinoizoksazolil, benzoksazolil, klorobenzoksazolil, fluorofenilbenzoksazolil, etilfenilbenzoksazolil, dimetilaminofenilbenzoksazolil, piridinilbenzoksazolil, benzotiazolil, acetamidobenzotiazolil, bromobenzotiazolil, klorobenzotiazolil, (kloro)(metil)benzotiazolil, (kloro)(metoksi)benzotiazolil, fluorobenzotiazolil, difluorobenzotiazolil, cijanobenzotiazolil, metilbenzotiazolil, dimetilbenzotiazolil, (metil)(metoksi)benzotiazolil, etilbenzotiazolil, trifluorometilbenzotiazolil, hidroksibenzotiazolil, metoksibenzotiazolil, etoksibenzotiazolil, izopropoksibenzotiazolil, trifluorometoksibenzotiazolil, difluorometoksibenzotiazolil, dimetoksibenzotiazolil, morfolinilbenzotiazolil, (pirolidinilCO)benzotiazolil, metilsulfonilbenzotiazolil, klorotiazolopiridinil, dimetiltiazolopiridinil, benziloksitiazolopiridinil, difluorometoksitiazolopiridinil, benzotriazolil, indolonil, indazolil, bromoindazolil, kloroindazolil, fluoroindazolil, (metil)(metoksi)indazolil, metoksiindazolil, trifluorometilindazolil, trifluorometoksiindazolil, difluorometoksiindazolil, benzimidazolil, fluorobenzimidazolil, metilbenzimidazolil, (metil)(metoksi)benzimidazolil, metoksibenzimidazolil, tetrahidrobenzotiazolil, furopiridinil, dimetilfuropirimidinil, tienopirimidinil, izopropiltienopirimidinil, dimetiltienopirimidinil, klorotriazolopiridinil, metiltriazolopiridinil, trifluorometiltriazolopiridinil, metoksitriazolopiridinil, triazolopirazinil, bromopirolotriazinil, dimetilaminotiazolopirimidinil, tiazolopiazinil, bromotiazolopiazinil, metoksitiazolopiazinil, metiltiotiazolopiazinil, metoksitiazolopirimidinil, (metil)(metoksi)tiazolopirimidinil, kinolinil, bromokinolinil, fluorokinolinil, metilkinolinil, (metil)(metoksi)kinolinil, izokinolinil, bromoizokinolinil, dikloroizokinolinil, metilizokinolinil, dimetilizokinolinil, kinoksalinil, klorokinoksalinil, metilkinoksalinil, metoksikinoksalinil, kinazolinil, bromokinazolinil, naftiridinil, 5,6-dihidrobenzo[h]kinazolinil, 5Hkromeno[4,3-d]pirimidinil, 6,7-dihidro-5H-ciklopenta[d]pirimidinil, 5,6,7,8-tetrahidrokinazolinil, i 7,8-dihidrokinazolin-5(6H)-onil;
ili njegova farmaceutski prikladna sol.
4. Spoj prema zahtjevu 1 gdje R1 se izabire iz grupe koja obuhvaća feniltiazolil, (kloro)(metil)piridinil, (bromo)(fenil)pirimidinil, metoksipirimidinil, difluorometoksipirimidinil, difluoroetoksipirimidinil, ciklopentoksipirimidinil, (metilfenil)pirimidinil, (metoksifenil)pirimidinil, bromopirazinil, kloropirazinil, metiltiopirazinil, metoksibenzotiazolil, etoksibenzotiazolil, difluorometoksibenzotiazolil, tiazolopiridinonil, trifluorometilindazolil, benzimidazolil, izokinoinil, i kinazolinil;
ili njegova farmaceutski prikladna sol.
5. Stereoizomer prema zahtjevu 1 prema Formuli Ia;
[image]
ili njegova farmaceutski prikladna sol.
6. Spoj prema zahtjevu 5 gdje R1 se izabire iz grupe koja obuhvaća dimetilizoksazolil, (metil)(fenil)izoksazolil, metilpirazolil, dimetilpirazolil, tienilpirazolil, metoksifenilpirazolil, tiazolil, bromotiazolil, cijanotiazolil; metiltiazolil, dimetiltiazolil, (metil)(fenil)tiazolil, izopropiltiazolil, butiltiazolil, benziltiazolil, metoksifenilmetiltiazolil, feniltiazolil, klorofeniltiazolil, metoksifeniltiazolil, (metoksifenil)(metil)tiazolil, piridiniltiazolil, (fenil)(metil)imidazolil, metiloksadiazolil, etiloksadiazolil, metiltiadiazolil, fluorofeniltiadiazolil, furiltiadiazolil, (dimetilkarboksamido)(metil)tiazolil, (pirolidinilCO)tiazolil, feniltriazolil, piridinil, bromopiridinil, kloropiridinil, (kloro)(fluoro)piridinil, (kloro)(metil)piridinil, dikloropiridinil, fluoropiridinil, cijanopiridinil, (cijano)(metil)piridinil, (cijano)(dimetil)piridinil, metoksipiridinil, (metilpirolidinil)piridinil, fenilpiridinil, metoksipiridinilpiridinil, piridazinil, bromopiridazinil, kloropiridazinil, metilpiridazinil, metoksipiridazinil, metiltiopiridazinil, pirolidinilpiridazinil, pirolidinonilpiridazinil, fenilpiridazinil, piridinilpiridazinil, metoksipiridinilpiridazinil, pirimidinil, (bromo)(izopropil)pirimidinil, (bromo)(dimetil)pirimidinil, (bromo)(ciklopropil)pirimidinil, (bromo)(metoksi)pirimidinil, (bromo)(fenil)pirimidinil, (bromo)(piridinil)pirimidinil, kloropirimidinil, (kloro)(dimetil)pirimidinil, (metil)(metoksi)pirimidinil, metilpirimidinil, etilpirimidinil, (metil)(fenil)pirimidinil, dimetilpirimidinil, butilpirimidinil, izopropilpirimidinil, ciklopropilpirimidinil, metoksipirimidinil, dimetoksipirimidinil, izopropoksipirimidinil, ciklopentoksipirimidinil, difluorometoksipirimidinil, trifluoroetoksipirimidinil, fenoksipirimidinil, metiltiopirimidinil, fenilpirimidinil, klorofenilpirimidinil, metilfenilpirimidinil, metoksifenilpirimidinil, (fenil)(triazolil)pirimidinil, piridinilpirimidinil, metoksipiridinilpirimidinil, metoksipirimidinilpirimidinil, naftilpirimidinil, pirazinil, bromopirazinil, (bromo)(metoksi)pirazinil, kloropirazinil, metilpirazinil, dimetilpirazinil, butilpirazinil, cijanopirazinil, metoksipirazinil, izopropoksipirazinil, trifluorometilpirazinil, i fenilpirazinil, i dimetiltriazinil;
ili njegova farmaceutski prikladna sol.
7. Spoj prema zahtjevu 5 gdje R1 se izabire iz grupe koja obuhvaća dimetilpiridinoizoksazolil, benzoksazolil, klorobenzoksazolil, fluorofenilbenzoksazolil, etilfenilbenzoksazolil, dimetilaminofenilbenzoksazolil, piridinilbenzoksazolil, benzotiazolil, acetamidobenzotiazolil, bromobenzotiazolil, klorobenzotiazolil, (kloro)(metil)benzotiazolil, (kloro)(metoksi)benzotiazolil, fluorobenzotiazolil, difluorobenzotiazolil, cijanobenzotiazolil,bmetilbenzotiazolil, dimetilbenzotiazolil, (metil)(metoksi)benzotiazolil, etilbenzotiazolil, trifluorometilbenzotiazolil, hidroksibenzotiazolil, metoksibenzotiazolil, etoksibenzotiazolil, izopropoksibenzotiazolil, trifluorometoksibenzotiazolil, difluorometoksibenzotiazolil, dimetoksibenzotiazolil, morfolinilbenzotiazolil, (pirolidinilCO)benzotiazolil, metilsulfonilbenzotiazolil, klorotiazolopiridinil, dimetiltiazolopiridinil, benziloksitiazolopiridinil, difluorometoksitiazolopiridinil, benzotriazolil, indolonil, indazolil, bromoindazolil, kloroindazolil, fluoroindazolil, (metil)(metoksi)indazolil, metoksiindazolil, trifluorometilindazolil, trifluorometoksiindazolil, difluorometoksiindazolil, benzimidazolil, fluorobenzimidazolil, metilbenzimidazolil, (metil)(metoksi)benzimidazolil, metoksibenzimidazolil, tetrahidrobenzotiazolil, furopiridinil, dimetilfuropirimidinil, tienopirimidinil, izopropiltienopirimidinil, dimetiltienopirimidinil, klorotriazolopiridinil, metiltriazolopiridinil, trifluorometiltriazolopiridinil, metoksitriazolopiridinil, triazolopirazinil, bromopirolotriazinil, dimetilaminotiazolopirimidinil, tiazolopiazinil, bromotiazolopiazinil, metoksitiazolopiazinil, metiltiotiazolopiazinil, metoksitiazolopirimidinil, (metil)(metoksi)tiazolopirimidinil, kinolinil, bromokinolinil, fluorokinolinil, metilkinolinil, (metil)(metoksi)kinolinil, izokinolinil, bromoizokinolinil, dikloroizokinolinil, metilizokinolinil, dimetilizokinolinil, kinoksalinil, klorokinoksalinil, metilkinoksalinil, metoksikinoksalinil, kinazolinil, bromokinazolinil, naftiridinil, 5,6-dihidrobenzo[h]kinazolinil, 5Hkromeno[4,3-d]pirimidinil, 6,7-dihidro-5H-ciklopenta[d]pirimidinil, 5,6,7,8-tetrahidrokinazolinil, i 7,8-dihidrokinazolin-5(6H)-onil;
ili njegova farmaceutski prikladna sol.
8. Spoj prema zahtjevu 5 gdje R1 se izabire iz grupe koja obuhvaća feniltiazolil, (kloro)(metil)piridinil, (bromo)(fenil)pirimidinil, metoksipirimidinil, difluorometoksipirimidinil, difluoroetoksipirimidinil, ciklopentoksipirimidinil, (metilfenil)pirimidinil, (metoksifenil)pirimidinil, bromopirazinil, kloropirazinil, metiltiopirazinil, metoksibenzotiazolil, etoksibenzotiazolil, difluorometoksibenzotiazolil, tiazolopiridinonil, trifluorometilindazolil, benzimidazolil, izokinoinil, i kinazolinil;
ili njegova farmaceutski prikladna sol.
9. Spoj prema zahtjevu 5 gdje R1 se izabire iz grupe koja obuhvaća tiazolil, piridinil, piridazinil, pirimidinil, pirazinil, benzotiazolil, tiazolopiridinil, indazolil, benzimidazolil, izokinoinil, i kinazolinil, i supstituiran je s 0-3 supstituenta nezavisno izabrana iz grupe koja obuhvaća C1-4alkil, C3-7cikloalkil, C1-4haloalkil, C1-4alkoksi, C1-4haloalkoksi., C3-7cikloalkoksi, C1-4alkiltio, fenoksi, benziloksi, halo, hidroksi, cijano, C1-4alkilsulfonil, NR2R3, pirolidinonil, metilendioksi, furil, tienil, triazolil, pirimidinil, naftil, C1-4alkilamido, CONR2R3, piridil, fenil, i benzil, i gdje su piridil, fenil, i benzil supstituirani s 0-2 supstituenta nezavisno izabrana iz grupe koja obuhvaća halo, C1-4alkil, C1-4alkoksi, C1-4haloalkil, C1-4haloalkoksi, i NR2R3;
ili njegova farmaceutski prikladna sol.
10. Spoj prema zahtjevu 9 gdje R1 se izabire iz grupe koja obuhvaća piridinil, pirimidinil, pirazinil, tiazolopiridinil, i izokinoinil, i supstituiran je s 0-3 supstituenta nezavisno izabrana iz grupe koja obuhvaća C1-4alkil, C3-7cikloalkil, C1-4haloalkil, C1-4alkoksi, C1-4haloalkoksi, C3-7cikloalkoksi, C1-4alkiltio, fenoksi, benziloksi, halo, hidroksi, cijano, C1-4alkilsulfonil, NR2R3, pirolidinonil, metilendioksi, furil, tienil, triazolil, pirimidinil, naftil, C1-4alkilamido, CONR2R3, piridil, fenil, i benzil, i gdje su piridil, fenil i benzil supstituirani s 0-2 supstituenta nezavisno izabrana iz grupe koja obuhvaća halo, C1-4alkil, C1-4alkoksi, C1-4haloalkil, C1-4haloalkoksi, i NR2R3;
ili njegova farmaceutski prikladna sol.
11. Spoj prema zahtjevu 10 gdje R1 se izabire iz grupe koja obuhvaća piridinil i izokinoinil, i supstituiran je s 0-3 supstituenta nezavisno izabrana iz grupe koja obuhvaća C1-4alkil, C3-7cikloalkil, C1-4haloalkil, C1-4alkoksi, C1-4haloalkoksi, C3-7cikloalkoksi, C1-4alkiltio, fenoksi, benziloksi, halo, hidroksi, cijano, C1-4alkilsulfonil, NR2R3, pirolidinonil, metilendioksi, furil, tienil, triazolil, pirimidinil, naftil, C1-4alkilamido, CONR2R3, piridil, fenil, i benzil, i gdje su piridil, fenil i benzil supstituirani s 0-2 supstituenta nezavisno izabrana iz grupe koja obuhvaća halo, C1-4alkil, C1-4alkoksi, C1-4haloalkil, C1-4haloalkoksi, i NR2R3;
ili njegova farmaceutski prikladna sol.
12. Spoj izabran iz grupe koja obuhvaća
[image]
[image]
i
[image]
ili njegova farmaceutski prikladna sol.
13. Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prikladne soli, i farmaceutski prikladan nosač.
14. Spoj prema bilo kojem od zahtjeva 1 do 12 za uporabu u liječenju shizofrenije ili Alzheimerove bolesti.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4721108P | 2008-04-23 | 2008-04-23 | |
| US12/423,299 US7863291B2 (en) | 2008-04-23 | 2009-04-14 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| EP09733949.3A EP2271650B1 (en) | 2008-04-23 | 2009-04-20 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| PCT/US2009/041076 WO2009131926A1 (en) | 2008-04-23 | 2009-04-20 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151111T1 true HRP20151111T1 (hr) | 2015-12-18 |
Family
ID=41215599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151111TT HRP20151111T1 (hr) | 2008-04-23 | 2015-10-21 | Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7863291B2 (hr) |
| EP (1) | EP2271650B1 (hr) |
| JP (1) | JP5389905B2 (hr) |
| KR (1) | KR20110015565A (hr) |
| CN (1) | CN102066384B (hr) |
| AR (1) | AR071215A1 (hr) |
| AU (1) | AU2009239575B2 (hr) |
| BR (1) | BRPI0911542A2 (hr) |
| CA (1) | CA2722325A1 (hr) |
| CL (1) | CL2009000975A1 (hr) |
| CO (1) | CO6300941A2 (hr) |
| CY (1) | CY1117045T1 (hr) |
| DK (1) | DK2271650T3 (hr) |
| EA (1) | EA017628B1 (hr) |
| ES (1) | ES2553753T3 (hr) |
| HR (1) | HRP20151111T1 (hr) |
| HU (1) | HUE028302T2 (hr) |
| IL (1) | IL208673A (hr) |
| MX (1) | MX2010011374A (hr) |
| NZ (1) | NZ588649A (hr) |
| PE (1) | PE20091977A1 (hr) |
| PL (1) | PL2271650T3 (hr) |
| PT (1) | PT2271650E (hr) |
| SI (1) | SI2271650T1 (hr) |
| TW (1) | TWI431007B (hr) |
| WO (1) | WO2009131926A1 (hr) |
| ZA (1) | ZA201007527B (hr) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309577B2 (en) * | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| ES2398684T3 (es) | 2008-04-23 | 2013-03-21 | Gilead Sciences, Inc. | Análogos de carbanucleósido para el tratamiento antiviral |
| AU2009279787B2 (en) * | 2008-08-04 | 2014-05-29 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| US8278320B2 (en) * | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| WO2011056573A1 (en) | 2009-10-28 | 2011-05-12 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| KR20120099060A (ko) * | 2009-10-29 | 2012-09-06 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-7 니코틴성 아세틸콜린 수용체 리간드로서의 퀴누클리딘 화합물 |
| MY159857A (en) | 2010-01-14 | 2017-02-15 | Sanofi Sa | 2,5-substituted oxazolopyrimidine derivatives |
| WO2011137313A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| PL2589592T3 (pl) | 2010-06-30 | 2019-03-29 | Fujifilm Corporation | Nowe pochodne nikotynamidu lub ich sole |
| BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
| US20120027752A1 (en) | 2010-07-22 | 2012-02-02 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| SG2014012926A (en) | 2011-08-30 | 2014-06-27 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013056070A2 (en) | 2011-10-14 | 2013-04-18 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| US9458179B2 (en) | 2012-05-24 | 2016-10-04 | Bristol-Myers Squibb Company | Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AU2014241065B2 (en) * | 2013-03-14 | 2017-08-31 | Merck Patent Gmbh | Glycosidase inhibitors |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| PE20161372A1 (es) | 2014-02-03 | 2017-01-08 | Vitae Pharmaceuticals Inc | Inhibidores de dihidropirrolopiridina de ror-gamma |
| JP5714745B2 (ja) * | 2014-04-28 | 2015-05-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
| US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| UA118989C2 (uk) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Дигідропіролопіридинові інгібітори ror-гамма |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| WO2016073407A1 (en) * | 2014-11-04 | 2016-05-12 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| BR112018005048B8 (pt) | 2015-09-16 | 2021-03-23 | Gilead Sciences Inc | uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae |
| MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| KR20180132060A (ko) | 2016-02-25 | 2018-12-11 | 아셰뉴론 에스아 | 피페라진 유도체의 산 부가 염 |
| EP3419971B1 (en) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| MX2018010191A (es) | 2016-02-25 | 2019-05-20 | Asceneuron S A | Inhibidores de glucosidasa. |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP4331677A3 (en) | 2017-03-14 | 2024-05-29 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| CR20190424A (es) | 2017-03-30 | 2019-11-04 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
| AU2017406159B2 (en) | 2017-03-30 | 2020-05-21 | XWPharma Ltd. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
| US10836787B2 (en) | 2017-05-01 | 2020-11-17 | Gilead Sciences, Inc. | Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| CN111225914B (zh) | 2017-07-24 | 2022-10-11 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| CN107868039A (zh) * | 2017-11-27 | 2018-04-03 | 中国药科大学 | 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法 |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| DK3788047T3 (da) | 2018-05-04 | 2024-09-16 | Incyte Corp | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20220143020A1 (en) | 2019-08-30 | 2022-05-12 | Sumitomo Dainippon Pharma Co., Ltd. | 2-aminoquinazolinone derivative |
| MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163424A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
| JP7554841B2 (ja) | 2020-03-12 | 2024-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシドを調製する方法 |
| US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
| KR20230018473A (ko) | 2020-05-29 | 2023-02-07 | 길리애드 사이언시즈, 인코포레이티드 | 렘데시비르 치료 방법 |
| CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
| AU2021331214B2 (en) | 2020-08-27 | 2024-01-04 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5053412A (en) * | 1990-04-10 | 1991-10-01 | Israel Institute For Biological Research | Spiro nitrogen-bridged heterocyclic compounds |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds |
| EP0777671B1 (en) | 1994-08-24 | 2000-04-26 | Astra Aktiebolag | Spiro-azabicyclic compounds useful in therapy |
| KR100998804B1 (ko) * | 2002-05-03 | 2010-12-06 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물,및 그에 유용한 신규 화합물 |
| WO2005005435A1 (en) | 2003-07-08 | 2005-01-20 | Astrazeneca Ab | Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| BRPI0518949A2 (pt) | 2004-12-15 | 2008-12-16 | Astrazeneca Ab | composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica |
| US20070004715A1 (en) * | 2005-06-30 | 2007-01-04 | Yifang Huang | Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders |
| ITMI20061279A1 (it) | 2006-06-30 | 2008-01-01 | Consiglio Nazionale Ricerche | Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US8309577B2 (en) * | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
-
2009
- 2009-04-14 US US12/423,299 patent/US7863291B2/en active Active
- 2009-04-20 PL PL09733949T patent/PL2271650T3/pl unknown
- 2009-04-20 EA EA201001696A patent/EA017628B1/ru not_active IP Right Cessation
- 2009-04-20 EP EP09733949.3A patent/EP2271650B1/en active Active
- 2009-04-20 KR KR1020107026057A patent/KR20110015565A/ko not_active Application Discontinuation
- 2009-04-20 WO PCT/US2009/041076 patent/WO2009131926A1/en active Application Filing
- 2009-04-20 HU HUE09733949A patent/HUE028302T2/en unknown
- 2009-04-20 BR BRPI0911542A patent/BRPI0911542A2/pt not_active IP Right Cessation
- 2009-04-20 SI SI200931324T patent/SI2271650T1/sl unknown
- 2009-04-20 NZ NZ588649A patent/NZ588649A/en unknown
- 2009-04-20 DK DK09733949.3T patent/DK2271650T3/en active
- 2009-04-20 JP JP2011506374A patent/JP5389905B2/ja not_active Expired - Fee Related
- 2009-04-20 CN CN200980123841.9A patent/CN102066384B/zh not_active Expired - Fee Related
- 2009-04-20 PT PT97339493T patent/PT2271650E/pt unknown
- 2009-04-20 ES ES09733949.3T patent/ES2553753T3/es active Active
- 2009-04-20 CA CA2722325A patent/CA2722325A1/en not_active Abandoned
- 2009-04-20 MX MX2010011374A patent/MX2010011374A/es active IP Right Grant
- 2009-04-20 AU AU2009239575A patent/AU2009239575B2/en not_active Ceased
- 2009-04-23 TW TW098113525A patent/TWI431007B/zh not_active IP Right Cessation
- 2009-04-23 PE PE2009000562A patent/PE20091977A1/es not_active Application Discontinuation
- 2009-04-23 AR ARP090101442A patent/AR071215A1/es unknown
- 2009-04-23 CL CL2009000975A patent/CL2009000975A1/es unknown
-
2010
- 2010-10-12 IL IL208673A patent/IL208673A/en not_active IP Right Cessation
- 2010-10-21 ZA ZA2010/07527A patent/ZA201007527B/en unknown
- 2010-10-22 CO CO10131169A patent/CO6300941A2/es active IP Right Grant
-
2015
- 2015-10-21 HR HRP20151111TT patent/HRP20151111T1/hr unknown
- 2015-12-14 CY CY20151101139T patent/CY1117045T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151111T1 (hr) | Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora | |
| JP2011518831A5 (hr) | ||
| CN105530932B (zh) | 作为btk抑制剂的伯甲酰胺 | |
| ES2434467T3 (es) | Compuestos multicíclicos y métodos para su uso | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| RS20060201A (en) | 1,1,1,-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo | |
| NO20064309L (no) | Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer | |
| HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
| HRP20220414T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| CA2478229A1 (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
| HRP20130202T1 (hr) | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis | |
| AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
| HRP20212021T1 (hr) | 4-IMIDAZOPIRIDAZIN-1-iL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI KAO INHIBITORI BTK | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| RS20050174A (en) | -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases | |
| AR060537A1 (es) | 1,2,4-triazoles trisustituidos | |
| GB201201744D0 (en) | Novel compounds | |
| CA2554049A1 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| HRP20161558T1 (hr) | Novi biciklički piridinoni | |
| MEP12508A (en) | Derivatives of n-/phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | |
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta |